This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
7 Multiline Insurers to Watch Out For as COVID-Led Challenges Ease
by Tanuka De
Better pricing, product redesigns and increased adoption of technology are expected to aid multiline insurers like CI, ORI, JRVR, HIG, PRU, AIG and MET. However, a low-rate environment remains a headwind.
MetLife's (MET) Unit Private Debt Portfolio Reaches $102.1B
by Zacks Equity Research
MetLife's (MET) institutional asset management business MIM undertakes private placement debt origination activity of $15.7 billion during 2020.
Why Is MetLife (MET) Up 13% Since Last Earnings Report?
by Zacks Equity Research
MetLife (MET) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AMERISAFE (AMSF) Beats Q4 Earnings Estimates, Hikes Dividend
by Zacks Equity Research
AMERISAFE's (AMSF) fourth-quarter results witness payroll audits and related premium adjustments partly benefiting premiums. However, lower revenues and elevated costs somewhat offset the results.
MetLife (MET) Unit With PRT Market Expertise to Aid Philips
by Zacks Equity Research
MetLife's (MET) subsidiary and Principal Financial ink deal in a bid to help Philips' retirement plan participants in attaining a secured future.
American International (AIG) Q4 Earnings Miss, Revenues Beat
by Zacks Equity Research
American International's (AIG) Q4 results are affected by catastrophe losses and the Fortitude divestiture, partly offset by better alternative investment returns.
Insurance ETFs Riding High on Robust Q4 Earnings
by Sweta Killa
The string of solid fourth-quarter earnings from the insurance industry players had a positive impact on the related ETFs that saw smooth trading over past week.
The Zacks Analyst Blog Highlights: Exxon Mobil, AbbVie, Caterpillar, Deere & Co and MetLife
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, AbbVie, Caterpillar, Deere & Co and MetLife
Q4 Earnings Season Scorecard and Analyst Reports for Exxon, AbbVie & Caterpillar
by Sheraz Mian
We have provided a real-time update on the Q4 earnings season in today's Research Daily, in addition to featuring new research reports on Exxon (XOM), AbbVie (ABBV) and Caterpillar (CAT).
Allstate's (ALL) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Allstate's (ALL) Q4 results reflect growth in earnings and revenues along with lower expenses.
Lincoln National (LNC) Earnings Miss in Q4, Decrease Y/Y
by Zacks Equity Research
Lincoln National's (LNC) Q4 results reflect higher revenues, partly offset by elevated pandemic-related claims.
MetLife (MET) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
MetLife's (MET) fourth-quarter results reflect uptick in revenues and sound underwriting results, partly offset by higher costs.
MetLife (MET) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
MetLife (MET) delivered earnings and revenue surprises of 32.68% and 29.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Insurance Stock Earnings Roster for Feb 3: MET, ALL & More
by Zacks Equity Research
Insurance companies are likely to have gained from improved pricing and lower auto claims, partly offset by high catastrophe claims.
MetLife (MET) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
MetLife's (MET) fourth-quarter results are likely to reflect lower interest rates and higher COVID-19 related claims, partly offset by strong underwriting margins.
Hartford Financial (HIG) Launches Plan for Mental Health
by Zacks Equity Research
Hartford Financial (HIG) introduces a plan to ease the financial stress of people suffering mental health illnesses.
The Zacks Analyst Blog Highlights: Novartis, QUALCOMM, Accenture, MetLife and Electronic Arts
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, QUALCOMM, Accenture, MetLife and Electronic Arts
Top Stock Reports for Novartis, QUALCOMM & Accenture
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), QUALCOMM (QCOM), and Accenture (ACN).
Aflac (AFL) Grows Product Menu Via New Dental & Vision Offers
by Zacks Equity Research
Aflac (AFL) introduces a dental and vision insurance package, thereby widening its product portfolio in the U.S. segment.
MetLife (MET) Unit to Reinsure Legal & General's Longevity Risk
by Zacks Equity Research
MetLife's (MET) subsidiary inscribes four agreements in a bid to foray deeper into the U.K. longevity risk transfer market.
Here's Why Hartford Financial (HIG) Stock is an Attractive Bet Now
by Zacks Equity Research
Hartford Financial (HIG) remains well-poised for growth on the back of impressive performance in Commercial Lines business and sound capital position.
AIG Declines 27% Year to Date: Will It Recover in 2021?
by Zacks Equity Research
AIG has undertaken a host of initiatives including dispositions, which raises hopes for the next year following a dismal period of COVID-19 induced business loss.
Hartford Financial (HIG) Unveils Share Buyback Program Worth $1.5B
by Zacks Equity Research
Hartford Financial's (HIG) board raises share buyback authorization, which showcases its sound financial standing and constant efforts to support prudent capital deployment.
Aflac (AFL) Down 13% in 2020: Will It Bounce Back in 2021?
by Zacks Equity Research
A slew of initiatives recently taken by Aflac (AFL) should aid the stock in 2021 after suffering from COVID-led business loss in 2020.
MetLife (MET) Dips 5% Year to Date: Will it Recover in 2021?
by Zacks Equity Research
Strategic initiatives, such as acquisitions and dispositions, strong business and a gradually improving economic environment will drive MetLife's (MET) shares in 2021.